Hal Barron (GSK via YouTube)
GSK bets $3.3B on a buyout, jumping into a blockbuster showdown with Pfizer and Merck
Count GSK in for the pneumococcal vaccine race.
The British pharma is wagering $2.1 billion in cash — plus up to $1.2 billion in milestones …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
